Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2011 Jan 8;1(12):1063–1072. doi: 10.1007/s13238-010-0140-9

Mdm2 links genotoxic stress and metabolism to p53

Zhongfeng Wang 1, Baojie Li 1,✉
PMCID: PMC4875075  PMID: 21213101

Abstract

Mouse double minute 2 (Mdm2) gene was isolated from a cDNA library derived from transformed mouse 3T3 cells, and was classified as an oncogene as it confers 3T3 and Rat2 cells tumorigenicity when overexpressed. It encodes a nucleocytoplasmic shuttling ubiquitin E3 ligase, with its main target being tumor suppressor p53, which is mutated in more than 50% of human primary tumors. Mdm2’s oncogenic activity is mainly mediated by p53, which is activated by various stresses, especially genotoxic stress, via Atm (ataxia telangiectasia mutated) and Atr (Atm and Rad3-related). Activated p53 inhibits cell proliferation, induces apoptosis or senescence, and maintains genome integrity. Mdm2 is also a target gene of p53 transcription factor. Thus, Mdm2 and p53 form a feedback regulatory loop. External and internal cues, through multiple signaling pathways, can act on Mdm2 to regulate p53 levels and cell proliferation, death, and senescence. This review will focus on how Mdm2 is regulated under genotoxic stress, and by the Akt1-mTOR-S6K1 pathway that is activated by insulin, growth factors, amino acids, or energy status.

Keywords: mouse double minute 2 (Mdm2), p53, signal transduction, tumorigenesis

References

  1. Allred D.C., Clark G.M., Elledge R., Fuqua S.A., Brown R.W., Chamness G.C., Osborne C.K., McGuire W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–206. doi: 10.1093/jnci/85.3.200. [DOI] [PubMed] [Google Scholar]
  2. Araki S., Eitel J.A., Batuello C.N., Bijangi-Vishehsaraei K., Xie X. J., Danielpour D., Pollok K.E., Boothman D.A., Mayo L.D. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest. 2010;120:290–302. doi: 10.1172/JCI39194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E., McMahon S.B. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol. 2002;22:5650–5661. doi: 10.1128/MCB.22.16.5650-5661.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Argentini M., Barboule N., Wasylyk B. The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene. 2000;19:3849–3857. doi: 10.1038/sj.onc.1203737. [DOI] [PubMed] [Google Scholar]
  5. Barak Y., Gottlieb E., Juven-Gershon T., Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 1994;8:1739–1749. doi: 10.1101/gad.8.15.1739. [DOI] [PubMed] [Google Scholar]
  6. Blattner C., Hay T., Meek D.W., Lane D.P. Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol. 2002;22:6170–6182. doi: 10.1128/MCB.22.17.6170-6182.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Blaydes J.P., Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene. 1998;16:3317–3322. doi: 10.1038/sj.onc.1201880. [DOI] [PubMed] [Google Scholar]
  8. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602. doi: 10.1016/j.cell.2004.11.022. [DOI] [PubMed] [Google Scholar]
  9. Brady M., Vlatkovic N., Boyd M.T. Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol. 2005;25:545–553. doi: 10.1128/MCB.25.2.545-553.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Buschmann T., Fuchs S.Y., Lee C.G., Pan Z.Q., Ronai Z. SUMO-1 modification of Mdm2 prevents its selfubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell. 2000;101:753–762. doi: 10.1016/s0092-8674(00)80887-9. [DOI] [PubMed] [Google Scholar]
  11. Buschmann T., Lerner D., Lee C.G., Ronai Z. The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9. J Biol Chem. 2001;276:40389–40395. doi: 10.1074/jbc.M103786200. [DOI] [PubMed] [Google Scholar]
  12. Busuttil V., Droin N., McCormick L., Bernassola F., Candi E., Melino G., Green D.R. NF-{kappa}B inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA. 2010;107(42):18061–18066. doi: 10.1073/pnas.1006163107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Candeias M.M., Malbert-Colas L., Powell D.J., Daskalogianni C., Maslon M.M., Naski N., Bourougaa K., Calvo F., Fåhraeus R. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol. 2008;10:1098–1105. doi: 10.1038/ncb1770. [DOI] [PubMed] [Google Scholar]
  14. Canner J.A., Sobo M., Ball S., Hutzen B., DeAngelis S., Willis W., Studebaker A.W., Ding K., Wang S., Yang D., et al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer. 2009;101:774–781. doi: 10.1038/sj.bjc.6605199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chang Y.C., Lee Y.S., Tejima T., Tanaka K., Omura S., Heintz N. H., Mitsui Y., Magae J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitinproteasome pathway. Cell Growth Differ. 1998;9:79–84. [PubMed] [Google Scholar]
  16. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 1993;13:4107–4114. doi: 10.1128/mcb.13.7.4107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Chen L., Marechal V., Moreau J., Levine A.J., Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J Biol Chem. 1997;272:22966–22973. doi: 10.1074/jbc.272.36.22966. [DOI] [PubMed] [Google Scholar]
  18. Cheng Q., Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle. 2010;9:472–478. doi: 10.4161/cc.9.3.10556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cheng Q., Chen L., Li Z., Lane W.S., Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009;28:3857–3867. doi: 10.1038/emboj.2009.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chi X.Z., Kim J., Lee Y.H., Lee J.W., Lee K.S., Wee H., Kim W.J., Park W.Y., Oh B.C., Stein G.S., et al. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 2009;69:8111–8119. doi: 10.1158/0008-5472.CAN-09-1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. de Oca Luna M., de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203–206. doi: 10.1038/378203a0. [DOI] [PubMed] [Google Scholar]
  22. Di Stefano V., Blandino G., Sacchi A., Soddu S., D’Orazi G. HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene. 2004;23:5185–5192. doi: 10.1038/sj.onc.1207656. [DOI] [PubMed] [Google Scholar]
  23. Dias S.S., Milne D.M., Meek D.W. c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF. Oncogene. 2006;25:6666–6671. doi: 10.1038/sj.onc.1209671. [DOI] [PubMed] [Google Scholar]
  24. Ding K., Lu Y., Nikolovska-Coleska Z., Wang G., Qiu S., Shangary S., Gao W., Qin D., Stuckey J., Krajewski K., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006;49:3432–3435. doi: 10.1021/jm051122a. [DOI] [PubMed] [Google Scholar]
  25. Dubs-Poterszman M.C., Tocque B., Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene. 1995;11:2445–2449. [PubMed] [Google Scholar]
  26. Efeyan A., Ortega-Molina A., Velasco-Miguel S., Herranz D., Vassilev L.T., Serrano M. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 2007;67:7350–7357. doi: 10.1158/0008-5472.CAN-07-0200. [DOI] [PubMed] [Google Scholar]
  27. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275:8945–8951. doi: 10.1074/jbc.275.12.8945. [DOI] [PubMed] [Google Scholar]
  28. Feng J., Tamaskovic R., Yang Z., Brazil D.P., Merlo A., Hess D., Hemmings B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem. 2004;279:35510–35517. doi: 10.1074/jbc.M404936200. [DOI] [PubMed] [Google Scholar]
  29. Fu W., Ma Q., Chen L., Li P., Zhang M., Ramamoorthy S., Nawaz Z., Shimojima T., Wang H., Yang Y., et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem. 2009;284:13987–14000. doi: 10.1074/jbc.M901758200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., O’Malley B.W., et al. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc Natl Acad Sci U S A. 2010;107:4579–4584. doi: 10.1073/pnas.0912094107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Fuchs S.Y., Adler V., Buschmann T., Wu X., Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene. 1998;17:2543–2547. doi: 10.1038/sj.onc.1202200. [DOI] [PubMed] [Google Scholar]
  32. Goldberg Z., Vogt Sionov R., Berger M., Zwang Y., Perets R., Van Etten R.A., Oren M., Taya Y., Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002;21:3715–3727. doi: 10.1093/emboj/cdf384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Grünbaum U., Meye A., Bache M., Bartel F., Würl P., Schmidt H., Dunst J., Taubert H. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line. Anticancer Res. 2001;21:2065–2071. [PubMed] [Google Scholar]
  34. Gu H., Wang X., Rao S., Wang J., Zhao J., Ren F.L., Mu R., Yang Y., Qi Q., Liu W., et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther. 2008;7:3298–3305. doi: 10.1158/1535-7163.MCT-08-0212. [DOI] [PubMed] [Google Scholar]
  35. Gu L., Zhu N., Findley H.W., Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia. 2008;22:730–739. doi: 10.1038/leu.2008.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Halaschek-Wiener J., Wacheck V., Kloog Y., Jansen B. Ras inhibition leads to transcriptional activation of p53 and downregulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal. 2004;16:1319–1327. doi: 10.1016/j.cellsig.2004.04.003. [DOI] [PubMed] [Google Scholar]
  37. Hjerpe R., Aillet F., Lopitz-Otsoa F., Lang V., Torres-Ramos M., Farrás R., Hay R.T., Rodríguez M.S. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation. Int J Biochem Cell Biol. 2010;42:725–735. doi: 10.1016/j.biocel.2010.01.010. [DOI] [PubMed] [Google Scholar]
  38. Hogan C., Hutchison C., Marcar L., Milne D., Saville M., Goodlad J., Kernohan N., Meek D. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem. 2008;283:18012–18023. doi: 10.1074/jbc.M709695200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Hollenhorst P.C., Shah A.A., Hopkins C., Graves B.J. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 2007;21:1882–1894. doi: 10.1101/gad.1561707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000;19:1473–1476. doi: 10.1038/sj.onc.1203464. [DOI] [PubMed] [Google Scholar]
  41. Inoue T., Geyer R.K., Howard D., Yu Z.K., Maki C.G. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001;276:45255–45260. doi: 10.1074/jbc.M107477200. [DOI] [PubMed] [Google Scholar]
  42. Iwakuma T., Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1:993–1000. [PubMed] [Google Scholar]
  43. Izumi T., Takaori-Kondo A., Shirakawa K., Higashitsuji H., Itoh K., Io K., Matsui M., Iwai K., Kondoh H., Sato T., et al. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology. 2009;6:1. doi: 10.1186/1742-4690-6-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Jones S., Roe A., Donehower L., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206–208. doi: 10.1038/378206a0. [DOI] [PubMed] [Google Scholar]
  45. Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 1993;8:3411–3416. [PubMed] [Google Scholar]
  46. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–323. doi: 10.1038/nature03097. [DOI] [PubMed] [Google Scholar]
  47. Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A. 1999;96:14973–14977. doi: 10.1073/pnas.96.26.14973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Kim D., Song J., Jin E.J. MicroRNA-221 regulates chondrogenic differentiation through promoting proteosomal degradation of slug by targeting Mdm2. J Biol Chem. 2010;285:26900–26907. doi: 10.1074/jbc.M110.115105. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  49. Kojima K., Konopleva M., Samudio I.J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L.T., et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150–3159. doi: 10.1182/blood-2005-02-0553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Kondo S., Barnett G.H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene. 1995;10:2001–2006. [PubMed] [Google Scholar]
  51. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948–953. doi: 10.1126/science.274.5289.948. [DOI] [PubMed] [Google Scholar]
  52. Lai K.P., Leong W.F., Chau J.F., Jia D., Zeng L., Liu H., He L., Hao A., Zhang H., Meek D., et al. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J. 2010;29:2994–3006. doi: 10.1038/emboj.2010.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Lee M.H., Lee S.W., Lee E.J., Choi S.J., Chung S.S., Lee J.I., Cho J.M., Seol J.H., Baek S.H., Kim K.I., et al. SUMOspecific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol. 2006;8:1424–1431. doi: 10.1038/ncb1512. [DOI] [PubMed] [Google Scholar]
  54. Li B. c-Abl in oxidative stress, aging and cancer. Cell Cycle. 2005;4:246–248. [PubMed] [Google Scholar]
  55. Li M., Brooks C.L., Kon N., Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell. 2004;13:879–886. doi: 10.1016/s1097-2765(04)00157-1. [DOI] [PubMed] [Google Scholar]
  56. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003;302:1972–1975. doi: 10.1126/science.1091362. [DOI] [PubMed] [Google Scholar]
  57. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., Donehower L.A. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 2007;12:342–354. doi: 10.1016/j.ccr.2007.08.033. [DOI] [PubMed] [Google Scholar]
  58. Lu X., Nguyen T.A., Zhang X., Donehower L.A. The Wip1 phosphatase and Mdm2: cracking the “Wip” on p53 stability. Cell Cycle. 2008;7:164–168. doi: 10.4161/cc.7.2.5299. [DOI] [PubMed] [Google Scholar]
  59. Maguire M., Nield P.C., Devling T., Jenkins R.E., Park B.K., Polański R., Vlatković N., Boyd M.T. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res. 2008;68:3232–3242. doi: 10.1158/0008-5472.CAN-07-5271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Maki C.G. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999;274:16531–16535. doi: 10.1074/jbc.274.23.16531. [DOI] [PubMed] [Google Scholar]
  61. Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24:1580–1589. doi: 10.1101/gad.1941710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Maya R., Balass M., Kim S.T., Shkedy D., Leal J.F., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001;15:1067–1077. doi: 10.1101/gad.886901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598–11603. doi: 10.1073/pnas.181181198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Meek D.W., Hupp T.R. The regulation of MDM2 by multisite phosphorylation—opportunities for molecular-based intervention to target tumours? Semin Cancer Biol. 2010;20:19–28. doi: 10.1016/j.semcancer.2009.10.005. [DOI] [PubMed] [Google Scholar]
  65. Meng L.H., Kohlhagen G., Liao Z.Y., Antony S., Sausville E., Pommier Y. DNA-protein cross-links and replicationdependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res. 2005;65:5337–5343. doi: 10.1158/0008-5472.CAN-05-0003. [DOI] [PubMed] [Google Scholar]
  66. Meulmeester E., Pereg Y., Shiloh Y., Jochemsen A.G. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle. 2005;4:1166–1170. doi: 10.4161/cc.4.9.1981. [DOI] [PubMed] [Google Scholar]
  67. Milne D., Kampanis P., Nicol S., Dias S., Campbell D.G., Fuller-Pace F., Meek D. A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein. FEBS Lett. 2004;577:270–276. doi: 10.1016/j.febslet.2004.09.081. [DOI] [PubMed] [Google Scholar]
  68. Mo P., Wang H., Lu H., Boyd D.D., Yan C. MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem. 2010;285:26908–26915. doi: 10.1074/jbc.M110.132597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Moll U.M., Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001–1008. [PubMed] [Google Scholar]
  70. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  71. Naski N., Gajjar M., Bourougaa K., Malbert-Colas L., Fåhraeus R., Candeias M.M. The p53 mRNA-Mdm2 interaction. Cell Cycle. 2009;8:31–34. doi: 10.4161/cc.8.1.7326. [DOI] [PubMed] [Google Scholar]
  72. Ofir-Rosenfeld Y., Boggs K., Michael D., Kastan M.B., Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32:180–189. doi: 10.1016/j.molcel.2008.08.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Pettersson S., Kelleher M., Pion E., Wallace M., Ball K.L. Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2. Biochem J. 2009;418:575–585. doi: 10.1042/BJ20082087. [DOI] [PubMed] [Google Scholar]
  74. Phelps M., Darley M., Primrose J.N., Blaydes J.P. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003;63:2616–2623. [PubMed] [Google Scholar]
  75. Pikkarainen S., Kennedy R.A., Marshall A.K., Tham L., Lay K., Kriz T.A., Handa B.S., Clerk A., Sugden P.H. Regulation of expression of the rat orthologue of mouse double minute 2 (MDM2) by H(2)O(2)-induced oxidative stress in neonatal rat cardiac myocytes. J Biol Chem. 2009;284:27195–27210. doi: 10.1074/jbc.M109.037887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Pochampally R., Fodera B., Chen L., Lu W., Chen J. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem. 1999;274:15271–15277. doi: 10.1074/jbc.274.21.15271. [DOI] [PubMed] [Google Scholar]
  77. Poyurovsky M.V., Katz C., Laptenko O., Beckerman R., Lokshin M., Ahn J., Byeon I.J., Gabizon R., Mattia M., Zupnick A., et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010;17:982–989. doi: 10.1038/nsmb.1872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Poyurovsky M.V., Priest C., Kentsis A., Borden K.L., Pan Z.Q., Pavletich N., Prives C. The Mdm2 RING domain Cterminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007;26:90–101. doi: 10.1038/sj.emboj.7601465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Qi J.S., Yuan Y., Desai-Yajnik V., Samuels H.H. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol. 1999;19:864–872. doi: 10.1128/mcb.19.1.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Ray, R.M., Bhattacharya, S., and Johnson, L.R. (2010). Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2010 Sep 2. [Epub ahead of print] DOI:10.1007/s10495-010-0538-0 [DOI] [PubMed]
  81. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell. 2000;103:321–330. doi: 10.1016/s0092-8674(00)00123-9. [DOI] [PubMed] [Google Scholar]
  82. Rong J.J., Hu R., Qi Q., Gu H.Y., Zhao Q., Wang J., Mu R., You Q.D., Guo Q.L. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 2009;284:102–112. doi: 10.1016/j.canlet.2009.04.011. [DOI] [PubMed] [Google Scholar]
  83. Samudio I.J., Duvvuri S., Clise-Dwyer K., Watt J.C., Mak D., Kantarjian H., Yang D., Ruvolo V., Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma. 2010;51:911–919. doi: 10.3109/10428191003731325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Sashida G., Liu Y., Elf S., Miyata Y., Ohyashiki K., Izumi M., Menendez S., Nimer S.D. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol. 2009;29:3687–3699. doi: 10.1128/MCB.01551-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Sato N., Mizumoto K., Maehara N., Kusumoto M., Nishio S., Urashima T., Ogawa T., Tanaka M. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res. 2000;20:837–842. [PubMed] [Google Scholar]
  86. Shangary S., Qin D., McEachern D., Liu M., Miller R.S., Qiu S., Nikolovska-Coleska Z., Ding K., Wang G., Chen J., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008;105:3933–3938. doi: 10.1073/pnas.0708917105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Sheikh M.S., Shao Z.M., Hussain A., Fontana J.A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res. 1993;53:3226–3228. [PubMed] [Google Scholar]
  88. Shinozaki T., Nota A., Taya Y., Okamoto K. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene. 2003;22:8870–8880. doi: 10.1038/sj.onc.1207176. [DOI] [PubMed] [Google Scholar]
  89. Slack A., Chen Z., Tonelli R., Pule M., Hunt L., Pession A., Shohet J.M. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005;102:731–736. doi: 10.1073/pnas.0405495102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Song M.S., Song S.J., Kim S.Y., Oh H.J., Lim D.S. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008;27:1863–1874. doi: 10.1038/emboj.2008.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Stad R., Little N.A., Xirodimas D.P., Frenk R., van der Eb A.J., Lane D.P., Saville M.K., Jochemsen A.G. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2001;2:1029–1034. doi: 10.1093/embo-reports/kve227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Stevenson L.F., Sparks A., Allende-Vega N., Xirodimas D.P., Lane D.P., Saville M.K. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007;26:976–986. doi: 10.1038/sj.emboj.7601567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Sun P., Dong P., Dai K., Hannon G.J., Beach D. p53-independent role of MDM2 in TGF-beta1 resistance. Science. 1998;282:2270–2272. doi: 10.1126/science.282.5397.2270. [DOI] [PubMed] [Google Scholar]
  94. Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y., El-Deiry W.S., Yang X. Critical role for Daxx in regulating Mdm2. Nat Cell Biol. 2006;8:855–862. doi: 10.1038/ncb1442. [DOI] [PubMed] [Google Scholar]
  95. Tortora G., Caputo R., Damiano V., Bianco R., Chen J., Agrawal S., Bianco A.R., Ciardiello F. A novel MDM2 antisense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer. 2000;88:804–809. doi: 10.1002/1097-0215(20001201)88:5<804::aid-ijc19>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  96. Truong A.H., Cervi D., Lee J., Ben-David Y. Direct transcriptional regulation of MDM2 by Fli-1. Oncogene. 2005;24:962–969. doi: 10.1038/sj.onc.1208323. [DOI] [PubMed] [Google Scholar]
  97. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45–53. doi: 10.1038/415045a. [DOI] [PubMed] [Google Scholar]
  98. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848. doi: 10.1126/science.1092472. [DOI] [PubMed] [Google Scholar]
  99. Wang P., Gao H., Ni Y., Wang B., Wu Y., Ji L., Qin L., Ma L., Pei G. Beta-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem. 2003;278:6363–6370. doi: 10.1074/jbc.M210350200. [DOI] [PubMed] [Google Scholar]
  100. Waning D.L., Lehman J.A., Batuello C.N., Mayo L.D. Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel) 2010;3:1576–1593. doi: 10.3390/ph3051576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Wood N.T., Meek D.W., Mackintosh C. 14-3-3 Binding to Pim-phosphorylated Ser166 and Ser186 of human Mdm2—Potential interplay with the PKB/Akt pathway and p14(ARF) FEBS Lett. 2009;583:615–620. doi: 10.1016/j.febslet.2009.01.003. [DOI] [PubMed] [Google Scholar]
  102. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–1132. doi: 10.1101/gad.7.7a.1126. [DOI] [PubMed] [Google Scholar]
  103. Yan J., Zhang D., Di Y., Shi H., Rao H., Huo K. A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. FEBS Lett. 2010;584:3275–3278. doi: 10.1016/j.febslet.2010.06.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Yang H.Y., Wen Y.Y., Lin Y.I., Pham L., Su C.H., Yang H., Chen J., Lee M.H. Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities. Oncogene. 2007;26:7355–7362. doi: 10.1038/sj.onc.1210540. [DOI] [PubMed] [Google Scholar]
  105. Zhang, X., Gu, L., Li, J., Shah, N., He, J., Yang, L., Hu, Q., and Zhou, M. (2010). Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. [Epub ahead of print] [PMID:20935220] Cancer Res 2010, 23. [DOI] [PMC free article] [PubMed]
  106. Zhang X.C., Chen J., Su C.H., Yang H.Y., Lee M.H. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 2008;103:1219–1230. doi: 10.1002/jcb.21504. [DOI] [PubMed] [Google Scholar]
  107. Zheng T., Wang J., Chen X., Meng X., Song X., Lu Z., Jiang H., Liu L. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumour Biol. 2010;31:287–295. doi: 10.1007/s13277-010-0035-7. [DOI] [PubMed] [Google Scholar]
  108. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433–439. doi: 10.1038/35044005. [DOI] [PubMed] [Google Scholar]
  109. Zhou B.P., Hung M.C. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol. 2002;29:62–70. doi: 10.1053/sonc.2002.34057. [DOI] [PubMed] [Google Scholar]
  110. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3:973–982. doi: 10.1038/ncb1101-973. [DOI] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES